Lilly(US:LLY) 智通财经网·2025-10-17 13:47Core Viewpoint - Eli Lilly (LLY.US) experienced a significant stock decline of over 4%, marking the largest intraday drop since August 7, with shares trading at $797.78. This was triggered by President Trump's comments regarding the potential reduction of the price of the diabetes drug Ozempic to as low as $150 per month, causing market volatility. However, CMS Administrator Mehmet Oz clarified that price negotiations are still ongoing and no agreement has been reached [1]. Company Summary - Eli Lilly's stock price fell over 4%, reaching $797.78, the largest drop since early August [1]. - The potential price reduction of Ozempic to $150 per month was highlighted by President Trump, which contributed to the market reaction [1]. - CMS Administrator Mehmet Oz stated that price negotiations for Ozempic are still in progress and no final agreement has been established [1].